SEATTLE--(BUSINESS WIRE)--Omeros Corporation today announced that OMS906 has received orphan drug designation from the U.S. Food and Drug Administration (FDA) for the treatment of paroxysmal nocturnal ...
A pioneering study demonstrates the promising capability of zero-shot large language models (LLMs) to analyze patient-reported symptom narratives and accurately differentiate between common peripheral ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results